MAPT and sleep apnea syndrome: Increased cerebrospinal fluid and blood levels of Amyloid-β peptide and phosphorylated Tau protein was reported in patients with sleep disturbances, including SDB [15], and have been considered biomarkers for disease progression [42,43,44].